We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Comparison of the Clinical Outcome of Ramucirumab for Unresectable Hepatocellular Carcinoma with That of Prior Tyrosine Kinase Inhibitor Therapy.
- Authors
Amioka, Kei; Kawaoka, Tomokazu; Ogawa, Yutaro; Kikukawa, Chihiro; Naruto, Kensuke; Yoshikawa, Yuki; Ando, Yuwa; Kosaka, Yumi; Uchikawa, Shinsuke; Morio, Kei; Fujino, Hatsue; Nakahara, Takashi; Murakami, Eisuke; Yamauchi, Masami; Tsuge, Masataka; Hiramatsu, Akira; Imamura, Michio; Fukuhara, Takayuki; Mori, Nami; Takaki, Shintaro
- Abstract
Introduction: The clinical outcome of ramucirumab in multi-molecular targeted agent (MTA) sequential therapy for unresectable hepatocellular carcinoma (u-HCC) was assessed in comparison with that of prior tyrosine kinase inhibitor (TKI) therapy. Methods: Sixteen patients who received ramucirumab as part of multi-MTA sequential therapy for u-HCC were enrolled in a retrospective, cohort study. Ramucirumab was started as 2nd line in 7 patients, 3rd line in 5 patients, and 4th line in 4 patients. Results: The overall response rate was 6.3%, the disease control rate (DCR) was 50.0%, median progression-free survival was 2.0 months (evaluated by mRECIST), median overall survival (OS) with ramucirumab was 7.9 months, and the median OS from 1st-line therapy was 28.1 months. One month after the start of ramucirumab, α-fetoprotein (AFP) decreased in 6 of 12 cases (50.0%), and the DCR in AFP-decreased cases was 83.3%. The DCR of ramucirumab was 66.7% in cases in which disease control was obtained by prior TKI therapy, whereas it was 0.0% in the cases in which disease control was not obtained by prior TKI therapy. Examining the adverse events, no new safety concerns were confirmed. Conclusion: The AFP response to ramucirumab and the treatment response to prior TKI therapy are associated with treatment response to ramucirumab.
- Subjects
THERAPEUTIC use of antineoplastic agents; SURVIVAL; PROTEIN-tyrosine kinase inhibitors; TREATMENT effectiveness; COMPARATIVE studies; DESCRIPTIVE statistics; HEPATOCELLULAR carcinoma
- Publication
Oncology, 2021, Vol 99, Issue 5, p327
- ISSN
0030-2414
- Publication type
Article
- DOI
10.1159/000514315